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Abstract
Advanced medullary thyroid cancers (MTCs) are now being treated with drugs that 
inhibit receptor tyrosine kinases, many of which involved in angiogenesis. Response 
rates vary widely, and toxic effects are common, so treatment should be reserved for 
MTCs likely to be responsive to these drugs. RET mutations are common in MTCs, but it 
is unclear how they influence the microvascularization of these tumors. We examined 
45 MTCs with germ-line or somatic RET mutations (RETmut group) and 34 with wild-
type RET (RETwt). Taqman Low-Density Arrays were used to assess proangiogenic gene 
expression. Immunohistochemistry was used to assess intratumoral, peritumoral and 
nontumoral expression levels of VEGFR1, R2, R3, PDGFRa, PDGFB and NOTCH3. We also 
assessed microvessel density (MVD) and lymphatic vessel density (LVD) based on  
CD31-positive and podoplanin-positive vessel counts, respectively, and vascular pericyte 
density based on staining for a-smooth muscle actin (a-SMA), a pericyte marker. 
Compared with RETwt tumors, RETmut tumors exhibited upregulated expression of 
proangiogenic genes (mRNA and protein), especially VEGFR1, PDGFB and NOTCH3. MVDs 
and LVDs were similar in the two groups. However, microvessels in RETmut tumors were 
more likely to be a-SMA positive, indicating enhanced coverage by pericytes, which 
play key roles in vessel sprouting, maturation and stabilization. These data suggest 
that angiogenesis in RETmut MTCs may be more intense and complete than that found 
in RETwt tumors, a feature that might increase their susceptibility to antiangiogenic 
therapy. Given their increased vascular pericyte density, RETmut MTCs might also benefit 
from combined or preliminary treatment with PDGF inhibitors.
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Introduction
Medullary thyroid carcinomas (MTCs) arise from the 
thyroid parafollicular cells and represent 1–2% of all 
thyroid cancers (Wells et  al. 2015). Surgical resection is 
the only effective treatment for these tumors (de Groot 
et al. 2006, Deshpande et al. 2011). Despite their relatively 
slow growth, MTCs are characterized by early metastatic 
spread, and the effective treatment of patients with 
advanced disease is still a major challenge (Ferreira & 
Maia 2013). Indeed, mean survival for patients with MTC 
is lower than that associated with more common thyroid 
cancers, and in the presence of distant metastases, the 
10-year rate drops as low as 40% (Chau & Haddad 2013).
Increasing knowledge of the distinct signaling 
pathways and genetic abnormalities involved in the 
pathogenesis of cancer has allowed the development of 
targeted molecular therapies (Ferreira & Maia 2013). Most 
MTCs are sporadic cancers, but a hereditary pattern is 
discernible in 25–30% of cases (Pusztaszeri et  al. 2014). 
Ninety-nine percent of these familial cases are caused by 
germ-line mutations in the receptor tyrosine kinase (RTK) 
gene RET. RET mutations are less common in sporadic 
MTCs, roughly half of which harbor somatic alterations 
of this gene (Wu et al. 2011). In the last few years, somatic 
mutations in the RAS oncogenes have also been identified 
in sporadic MTCs, with reported prevalence rates ranging 
from 11% (Ciampi et  al. 2013) to 44% (Boichard et  al. 
2015). Nevertheless, in a small proportion of sporadic 
MTCs, no genetic alterations are detected.
Small-molecule inhibitors of receptor tyrosine 
kinases (TKIs) are one of the most promising approaches 
for treating MTCs. Indeed, encouraging results have 
emerged from clinical trials in which these drugs were 
tested in MTC (Ferreira & Maia 2013). The TKIs most 
widely investigated in MTC patients are drugs that target 
multiple RTKs, including those involved in angiogenesis 
like VEGFRs and PDGFRs. The efficacy of these agents 
varies widely, with partial responses reported in 0–40% 
of MTC patients and disease stabilization in 27–55% 
(Ferreira & Maia 2013). Unfortunately, TKIs also interact 
with receptors that mediate physiological functions and 
are thus associated with a number of highly toxic side 
effects. Careful advance selection of the patients likely 
to be responsive to these drugs is, therefore, essential. 
In-depth analysis of the molecular alterations present in 
the tumor is fundamental for selecting the most effective 
drug treatment. For example, MTC response rates to 
vandetanib, one of the most promising TKIs, are higher 
in RET M918T mutation-positive patients than in those 
without this mutation, and patients with RET-activating 
mutations at codon 804 (V804L, V804M) are resistant to 
vandetanib and some other TKIs as well (Ferreira & Maia 
2013).
Like most endocrine tumors, MTC are richly 
vascularized, and impairment of tumor vascularization 
may be at least one of the mechanisms underlying the 
TKIs’ therapeutic effects in these tumors. However, it 
is not clear whether specific molecular alterations in 
MTCs influence the features of angiogenesis and tumor 
microvascularization in MTC and, if so, what impact 
they have on the response to TKI therapy. To address 
these questions, we conducted an analysis of the genetic 
alterations and features of tumor microvascularity in a 
large series of MTCs.
Methods
Patients, tissues and cell lines
This study was approved by the research ethics committees 
of all participating centers. Written informed consent 
was obtained from each enrolled tissue donor. Unless 
otherwise specified, commercial products were used in 
accordance with the manufacturer’s instructions.
A total of 79 MTCs were examined. The 53 tumors for 
which fresh frozen tissue samples were available were used 
for gene expression analyses. These fresh frozen tissue 
samples were also subjected to mutation analysis, along 
with formalin-fixed paraffin-embedded (FFPE) samples 
from 26 other tumors (total: 79). Immunohistochemical 
analyses were performed on all FFPE samples (representing 
a total of 35 MTCs) and on a tissue microarray containing 
samples of 30 other tumors. The array was constructed 
according to standard procedures and included three 
separate cores (diameter: 0.6 mm) from each MTC. 
Histology sections from all tumor specimens (snap-
frozen and FFPE) were reviewed by two pathologists 
with experience in thyroid disease (G T and G P C), who 
confirmed the diagnosis of MTC and the adequacy of the 
neoplastic cell population in each sample analyzed.
TT cells were purchased from the American Type 
Culture Collection (Manassas, VA, USA). They are derived 
from a primary MTC and harbor a cysteine 634 to 
tryptophan (C634W) mutation in RET exon 11. TT cells 
were grown in Ham’s F12 Medium with 10% fetal bovine 
serum (FBS) (Gibco). The MZ-CRC1 cell line (kindly 
provided by Dr M Santoro) harbors a methionine 918 
to tryptophan (M918T) mutation in RET exon 16. These 
cells were grown in DMEM with 10% FBS. The media used 
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for both cultures were supplemented with 2 mmol L−1 
glutamine and 100 U/mL penicillin–streptomycin (Gibco).
Sanger sequencing
FFPE or fresh frozen tumor tissues from each MTC were 
subjected to Sanger sequencing to identify mutations 
involving the RET (exons 10, 11, 13, 14, 15, and 16), 
H-RAS, K-RAS and N-RAS genes (exons 2, 3 and 4). DNA 
was extracted using the NucleoSpin Tissue Kit (Macherey-
Nagel GmbH & Co. KG, Düren, Germany).
Primers and PCR conditions used for these analyses 
have been described elsewhere (Castellone et  al. 2010, 
Puppin et  al. 2014). Amplicons were purified with the 
NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel 
GmbH & Co. KG Düren, Germany) and sequenced with 
the BigDye Terminator Cycle Sequencing Kit, version 3.1 
(Thermo Fisher Scientific). Sequencing reactions were 
purified using the NucleoSEQ Kit (Macherey-Nagel) and 
loaded onto an ABI 3130xl Genetic Analyzer (Thermo 
Fisher Scientific). Data were analyzed with Sequencing 
Analysis software, version 5.3 (Thermo Fisher Scientific). 
Each mutation was confirmed twice, starting from the 
PCR step. Somatic and germ-line RET mutations were 
distinguished on the basis of DNA sequencing data of 
nontumor thyroid tissue samples from the same patient.
Angiogenic gene expression in fresh frozen  
tumor tissues
Total RNA was extracted from fresh frozen tumor 
tissues and reverse-transcribed, as described previously 
(Puppin et  al. 2014, Sponziello et  al. 2014). Angiogenic 
gene transcript levels were measured with real-time PCR 
performed with custom-designed microfluidic cards 
(Taqman Low-Density Arrays [TLDAs], Thermo Fisher 
Scientific), each configured with the specific Taqman 
Gene Expression Assay (Thermo Fisher Scientific) for 
the main components of the Notch pathway (receptors: 
NOTCH1, 2, 3, 4; ligands: DLL1, DLL3, DLL4, JAG1, JAG2; 
regulators: the gamma-secretases PSEN1 and 2, DTX1, 
MAML1 and RBPJ; effectors: HES1, HEY1-2-L; the repressor 
NUMB); the vascular endothelial growth factor (VEGF) 
pathway (ligands: VEGFA and VEGFC; receptors VEGFR1, 
2 and 3 and NRP1); and the platelet-derived growth factor 
(PDGF) pathway (ligands: PDGFA, PDFGB; receptors: 
PDGFRa and PDGFRb); as well as for the following genes: 
angiopoietin-1 and -2, MMPs 1-2-3-9, and TIMPs 1-2-3. 
Three housekeeping genes (GAPDH, GUSB and B2M) were 
included in each run for data normalization purposes. 
The reactions were set up as described previously 
(Sponziello et  al. 2014), and the amplifications were 
performed using a 7900HT Fast Real-Time PCR System 
(Thermo Fisher Scientific). Ct values were calculated 
with SDS 2.3 software (Thermo Fisher Scientific), and the 
detection threshold was set at 33. Data were analyzed with 
RQ Manager 1.2 software (Thermo Fisher Scientific). GAPDH 
was selected as the endogenous control gene because of its 
stability in the biological replicates. Results were determined 
by the 2−∆∆Ct method (Puppin et al. 2014) and expressed as 
relative expression normalized to a calibrator sample.
Immunohistochemical analysis of angiogenic  
marker expression and microvessel and lymphatic  
vessel densities
Immunohistochemistry was used to obtain protein-
level verification of the results of the angiogenic gene 
expression analyses described above. These studies were 
performed according to standard procedures (Tallini 
et  al. 1998) using a BenchMark XT automated platform 
(Ventana Medical Systems, Tucson, AZ, USA) and biotin-
free detection procedures. Angiogenic protein expression 
was analyzed in 30 FFPE tumor sections and in tissue 
microarray sections representing 35 MTCs. In each 
section, we scored the intensity of immunoreactivity in 
individual cells (weak = 1, moderate = 2, strong = 3) and 
the percentage of immunoreactive cells (<5% positive 
cells = 0, 5–24% positive cells = 1, 25–75% positive cells = 2, 
>75% positive cells = 3). The product of these two scores 
provided a semiquantitative index of expression (range: 
0–9). For each analyzed protein, labeled cells were counted 
in three areas: tumor tissue (zone T), peritumoral tissue 
(i.e. <2 mm from the tumor) (zone T/N) and nontumoral 
tissue (>2 mm from the tumor) (zone N).
Microvessel and lymphatic vessel densities (MVD 
and LVD, respectively) were evaluated in FFPE sections 
using the Weidner protocol with minor modifications, 
as reported previously (Durante & Filetti 2011). For 
assessment of MVD, vascular endothelial cells were 
identified with anti-CD31 antibodies; for LVD studies, 
lymphatic endothelial cells were identified with 
antibodies against podoplanin. FFPE sections were also 
stained with antibodies against α smooth muscle actin 
(a-SMA), a phenotypic marker used to identify pericytes. 
CD31-, podoplanin- and a-SMA-positive microvessels 
were counted in zones T, T/N and N.
Antibodies Mouse monoclonal antibody against 
VEGFR1 (dilution 1:500), rabbit polyclonal antibody 
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against PDGFB (1:100) and mouse monoclonal 
antibody against NOTCH3 (1:100) were obtained 
from Abcam. Rabbit monoclonal antibody against 
VEGFR2 (1:500) and rabbit monoclonal antibody 
against PDGFRa (1:500) were from Cell Signaling, and 
mouse monoclonal antibody against VEGFR3 (KLT9 
clone) (1:50) was purchased from Novocastra-Leica 
Biosystems (Newcastle, UK). Antibodies against CD31 
(JC70 clone), podoplanin (D2-40 clone) and a-SMA 
(1A4 clone) were purchased from Ventana Medical 
Systems, Tucson, AZ, USA).
Short interfering RNA (siRNA) silencing of RET in MTC 
cell lines
TT and MZ-CRC1 cells were plated at 40% confluence 
in 35 mm dishes containing Ham’s F12 Medium (TT 
cells) or DMEM (MZ-CRC1 cells) supplemented with 
4% FBS. Twenty-four hours later, cells were transfected 
with 100 nmol L−1 duplex siRNAs (ON-target plus 
SMARTpool) against human RET (siRET; # L-003170-00) 
(Dharmacon, Lafayette, CO, USA) using Dharmafect 
reagent. Control cells (CTL) were transfected with 
a nontargeting pool of siRNA (# D-001206-13-05). 
Twenty-four and forty-eight hours after transfection, 
cells were harvested for analysis of angiogenic gene 
expression, as described below.
Angiogenic gene expression analysis RNA for 
these assays was isolated with the RNeasy kit (Qiagen). 
The RNA concentration was measured with a NanoDrop 
Spectrophotometer (Thermo Fisher Scientific). RNA 
was retrotranscribed using the High Capacity cDNA 
Reverse Transcription kit (Thermo Fisher Scientific). 
Complementary DNA was analyzed with Taqman Gene 
Expression Assays-on-Demand (Thermo Fisher Scientific) 
to quantify the expression of VEGFA, VEGFR2, PDGFA, 
PDGFB, PDGFRa, PDGFRb, NOTCH1, NOTCH3, JAG1, 
JAG2, DLL4, HES1, HES5, HEY1, HEY2 and HEYL genes. 
The GADPH gene was used as an endogenous reference. 
Results (determined with the 2−∆∆Ct method) were 
normalized to corresponding calibrator samples and 
expressed as mean ± s.d. of three replicates.
Western blotting analysis and Human Phospho-
RTK array Total protein was extracted from TT and 
MZ-CRC1 cells using a buffer consisting of 150 mmol L−1 
Tris–HCl pH 7.4, 50 mmol L−1 NaCl, Triton 1%, EDTA 
20 mmol L−1, glycerol 5%, protease inhibitor cocktail 
(PIERCE, Thermo Fisher Scientific), 2 mmol L−1 PMSF 
and 2 µg/mL leupeptin. RET protein was detected with 
monoclonal anti-RET antibody (Cell Signaling #3220) 
produced in rabbits (dilution 1:1000). Phosphorylated 
and total ERK protein were detected with monoclonal 
anti-phospho-ERK1/2 (Thr202/Tyr204) antibody (Cell 
Signaling #4370) and with monoclonal anti-ERK1/2 
antibody (Cell Signaling #4695), both produced in rabbits 
(dilution 1:2000 and 1:1000).
Phosphorylated and total AKT proteins were detected 
with anti-phospho-AKT (Ser473) antibody (Cell Signaling 
#4058) and with anti-AKT antibody (Cell Signaling #9272), 
both produced in rabbits (dilution 1:1000). JAGGED1 
protein was detected with anti-JAGGED1 antibody (Santa 
Cruz sc-8303) produced in rabbits (dilution 1:1000). DLL4 
protein was detected with polyclonal anti-DLL4 antibody 
(Abcam ab176876) produced in rabbits (dilution 1:1000). 
Tubulin was detected with monoclonal antitubulin 
antibody (Santa Cruz sc-5286) produced in mice (dilution 
1:5000).
The protein lysates were also hybridized on Human 
Phospho-RTK array membranes (R&D Systems) to assess 
the phosphorylation levels of RET, VEGFRs and PDGFRs. 
The average signal (pixel density) of the pair of duplicate 
spots of each RTK was normalized to the negative control 
spots used as background value. Phosphorylated RTKs 
were detected using chemiluminescence with Clarity 
Western ECL substrate (BIO-RAD) and a charge-coupled 
device camera (Chemidoc, Bio-Rad). Data were analyzed 
with Image Lab software (Bio-Rad).
Statistical analysis
All statistical analyses were carried out with GraphPad 
Prism software, version 5.0 (GraphPad Software). TLDA 
results are expressed as mean ± s.d. The Mann–Whitney 
test was used to evaluate intergroup differences. The 
results of real-time PCR analysis of TT and MZ-CRC1 cell 
lines were expressed as group mean ± s.d., and intergroup 
differences were analyzed with the t-test. Phospho-RTK 
array data were expressed as mean pixel density ± s.d., 
and differences were assessed with a t-test. IHC scores 
were analyzed as follows: intergroup differences in 
CD31, podoplanin and a-SMA expression were analyzed 
with one-way RM ANOVA and two-way RM ANOVA 
with the Bonferroni multiple comparison post-test. 
Intergroup differences in the expression levels of all 
other proteins were assessed with the Friedman test or 
the Kruskal–Wallis test, each used with Dunn’s multiple 
comparisons test. P values <0.05 were considered 
statistically significant.
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Results
RET and RAS mutational profiles of the 79 MTCs
The RET/RAS mutational profiles of the 79 MTCs are 
summarized in Supplementary Table 1, see section on 
supplementary data given at the end of this article. On 
the basis of these findings, 45 MTCs were classified as 
RET-mutant (RETmut), 23 as RASmut tumors and the 
remaining 11 were characterized by wild-type (wt) 
forms of both genes (RETwt/RASwt tumors).
Expression of angiogenesis-related genes in MTCs
The expression of 36 angiogenesis-related genes was 
analyzed in fresh frozen tissue samples of 53 MTCs. As 
shown in Table  1, comparison of RETmut (n = 33) and 
RETwt (n = 20) tumors revealed significant upregulation in 
the former group of almost all the genes considered. Next, 
we compared expression levels for the same 36 genes in the 
RETmut and RASmut subgroups, using the RETwt/RASwt 
subgroup as a calibrator (Supplementary Table  2). This 
analysis revealed that the diffuse angiogenesis-related 
gene upregulation observed in the RETmut tumors 
(Table  1) was largely due to the differences in gene 
expression between the RETmut and RASmut subgroups 
(Supplementary Table 2).
RET induction of angiogenic factors
To confirm the link between RET oncogene activation 
and the overexpression of important factors involved 
in angiogenesis, we transfected two stable human MTC 
cell lines with RET antisense RNA (siRET). The strongest 
effect of siRET on TT and MZ-CRC1 cells was observed 
48 h after treatment, when there were significant 
reductions in both RET mRNA and protein levels 
(Supplementary Fig. 1A, B, C, and D). The efficacy of RET 
knockdown at 48 h was further confirmed by a decrease 
in RET phosphorylation (Supplementary Fig.  1E and 
G) with consequent reduction in phosphorylated ERK 
and AKT (pERK and pAKT, respectively) (Supplementary 
Fig.  1F and H). Subsequent analyses were, therefore, 
performed on cells harvested at this post-transfection 
time point. 
Our next goal was to see how RET knockdown 
affected the expression of genes playing key roles in 
the VEGF, PDGF and Notch pathways, all of which 
were significantly dysregulated in the RETmut MTCs 
we analyzed (Table  1). As shown in Fig.  1A and B, 
transcription of VEGFA, VEGFR2 and PDGFRb was 
significantly downregulated in both cell lines 48 h 
post-transfection. TT cells also displayed significant 
reductions in PDGFRa and PDGFB expression. Receptor 
phosphorylation was analyzed to assess the activation 
state of VEGF and PDGF pathways. Levels of pVEGFR2, 
pVEGFR3 and pPDGFRb were reduced in both cell lines 
(Fig. 1C and D). As shown in Fig. 1E and F, analysis of 
genes encoding Notch pathway components revealed 
no significant change after RET knockdown in the 
expression of NOTCH effector genes (except for HES5 in 
MZ-CRC1 cell line). To explore the possibility that RET 
Table 1 Expression levels of genes involved in angiogenesis 
and RET status.
RETwta
n = 20
RETmutb
n = 33 P valuec
VEGFA 1 ± 1.22 1.37 ± 0.67 <0.01
VEGFC 1 ± 1.03 1.40 ± 1.30 NS
VEGFR1 1 ± 0.82 1.88 ± 1.34 <0.01
VEGFR2 1 ± 0.74 2.21 ± 1.33 <0.001
VEGFR3 1 ± 0.96 1.64 ± 1.00 <0.05
NRP1 1 ± 0.55 1.50 ± 0.89 <0.05
PDGFA 1 ± 0.59 1.80 ± 1.13 <0.01
PDGFB 1 ± 0.55 1.82 ± 1.27 <0.01
PDGFRa 1 ± 1.20 5.55 ± 5.73 <0.001
PDGFRb 1 ± 0.70 2.51 ± 1.62 <0.001
NOTCH1 1 ± 0.78 1.98 ± 1.54 <0.01
NOTCH2 1 ± 1.03 1.88 ± 1.37 <0.01
NOTCH3 1 ± 0.80 2.27 ± 1.57 <0.01
NOTCH4 1 ± 0.83 2.15 ± 1.50 <0.01
DLL1 1 ± 0.77 1.01 ± 0.50 NS
DLL3 1 ± 1.60 1.20 ± 1.38 NS
DLL4 1 ± 0.52 1.61 ± 1.41 <0.05
JAG1 1 ± 1.07 1.41 ± 0.74 <0.01
JAG2 1 ± 0.66 1.79 ± 1.31 <0.01
PSEN1 1 ± 0.39 1.24 ± 0.43 NS
PSEN2 1 ± 0.43 1.40 ± 0.58 <0.05
DTX1 1 ± 1.31 1.44 ± 2.35 NS
RBPJ 1 ± 0.77 1.27 ± 0.59 <0.05
HES1 1 ± 0.57 1.51 ± 1.15 NS
HEY1 1 ± 0.47 2.01 ± 1.43 <0.01
HEY2 1 ± 0.53 2.05 ± 1.47 <0.01
HEYL 1 ± 0.70 2.53 ± 1.81 <0.01
MAML1 1 ± 0.43 1.68 ± 0.84 <0.01
NUMB 1 ± 0.41 1.27 ± 0.44 NS
ANGPT1 1 ± 0.87 1.60 ± 1.42 NS
ANGPT2 1 ± 1.07 2.06 ± 1.77 <0.01
MMP2 1 ± 1.19 2.06 ± 1.91 <0.01
MMP9 1 ± 3.43 0.73 ± 2.75 NS
TIMP1 1 ± 0.60 1.18 ± 0.42 NS
TIMP2 1 ± 1.40 0.71 ± 0.37 NS
TIMP3 1 ± 1.27 1.28 ± 1.27 NS
aIncludes all MTCs with wt RET (regardless of RAS status); bIncludes all 
MTCs with RET mutations (regardless of RAS status); cMann–Whitney.
Results are calculated with 2−∆∆Ct method and expressed as mean ± s.d. 
normalized to RETwt group, used as calibrator sample.
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activation could contribute to the activation of Notch 
signaling in other cells of the tumor (e.g. endothelial 
cells in the tumor microenvironment), we analyzed 
the expression of DLL4 and JAG1, two of the NOTCH 
ligands that appeared to be significantly dysregulated 
in the RETmut MTC (Table  1). Notably, JAG1 protein 
levels decreased appreciably after RET silencing in the 
MZ-CRC1 cells, and DLL4 expression diminished in 
both cell lines (Fig. 1G).
IHC analysis of proangiogenic protein expression and of 
microvessel, lymphatic vessel and vascular pericyte 
density in MTC
To verify the results of the angiogenic gene expression 
analysis shown in Table 1, we assessed the protein-level 
expression of six of the genes that were upregulated in 
RETmut MTCs. Given the limited availability of tumor 
specimens, we restricted this analysis to the proteins 
most likely to provide a comprehensive picture of in vivo 
Figure 1
Gene and protein expression analysis in MTC cell 
lines after RET knockdown. TT and MZ-CRC1 cells 
were transfected with siRET or with a 
nontargeting pool of siRNAs (CTL) and analyzed 
48 h later. Untreated cells (NT) were used as 
calibrators (data not shown). Panels A and B: 
mRNA levels (in TT and MZ-CRC1 cells, 
respectively) for genes encoding VEGF and PDGF 
pathway components. Panels C and D: VEGFR and 
PDGFR phosphorylation levels determined with 
the Human Phospho-RTK array. Data are 
expressed as average signal (pixel density) of the 
pair duplicate spots, normalized to negative 
control spots used as background value. Panels E 
and F: mRNA levels (in TT and MZ-CRC1 cells, 
respectively) for genes encoding Notch pathway 
components. Panel G: Protein expression levels in 
both cell lines of Notch ligands DLL4 and JAG1 
before and after RET knockdown. Data were 
analyzed with unpaired t test (*P < 0.05, 
**P < 0.01, ***P < 0.001).
Figure 2
Representative results of immunohistochemical 
staining of six proangiogenic proteins in MTCs 
showing the localization of each protein in tumor 
cells (*) and/or in endothelial cells (arrows). 
Magnification: 400×. A full colour version of this 
figure is available at http://dx.doi.org/10.1530/
ERC-16-0132.
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angiogenesis: VEGFR-1, -2, -3 and PDGFRa, the main 
receptors triggering angiogenic signaling, and PDGFB and 
NOTCH3, which are involved in pericyte recruitment, 
the final step of angiogenesis. IHC analysis of 63 FFPE 
tumor samples (43 RETmut, 15 RASmut, 5 RETwt/RASwt) 
revealed no genotype-related differences in the cellular 
(tumor vs endothelial cell) or subcellular localization of 
any of the proangiogenic proteins analyzed. Three of the 
receptors (VEGFR1, VEGFR3 and PDGFRa) and PDGFB 
(the only ligand considered) were more strongly expressed 
in tumor cells. VEGFR2 was expressed predominantly 
in endothelial cells, and NOTCH3 was expressed 
exclusively by these cells. VEGF receptors 1, 2 and 3, 
PDGFRa and NOTCH3 were found in the cytoplasm and 
plasma membrane. The expression of PDGFB ligand was 
predominantly cytoplasmic. A representative IHC image 
is shown in Fig. 2.
When all the samples were analyzed (independently 
from their mutational status), all angiogenic proteins 
displayed significantly higher mean expression scores 
in zone  T (tumor tissue) than in non-neoplastic tissue 
(zone  N) (Fig.  3). For VEGFR1, VEGFR2, PDGFB and 
NOTCH3 (but not VEGFR3 or PDGFRa), the mean scores 
for zone T/N were also significantly higher than those of 
zone N. The analyses were then repeated for the RETmut vs 
RETwt subgroups (Fig. 4). T-zone scores were all appreciably 
Figure 3
Immunohistochemical scores of proangiogenic 
protein expression (A, VEGFR1; B, VEGFR2;  
C, VEGFR3; D, PDGFRa; E, PDGFB; F, NOTCH3)  
in all 63 MTC samples by zone: T, tumor;  
T/N peritumoral non-neoplastic tissues (vessels 
located within 2 mm of the tumor front are 
considered peritumoral); N, non-neoplastic tissues 
at a distance (>2 mm) from the tumor. Friedman 
test with Dunn’s multiple comparison test. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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higher in sections from RETmut tumors, but the difference 
was significant only for VEGFR1, PDGFB and NOTCH3. 
(As shown in Supplementary Fig.  2, these findings were 
mainly due to differences between RETmut and RASmut 
tumors and, in the case of NOTCH3, also between RETmut 
and RETwt/RASwt tumors.) T/N scores were similar in the 
three groups of tumors (Fig. 4 and Supplementary Fig. 2).
Microvessel density (CD31 staining), lymphatic 
vascular density (podoplanin staining) and vascular 
pericyte density (a-SMA staining) were assessed in 28 
MTCs (4 RETwt/RASwt, 10 RASmut and 14 RETmut with 
somatic mutations). MTCs were highly vascular. CD31-
positive endothelial cells were more numerous inside the 
tumor; their density decreased at the interface between 
the tumor and the non-neoplastic peritumoral tissue (T/N) 
Figure 4
IHC analysis of proangiogenic protein expression 
in zones T, T/N and N of RETmut vs RETwt MTCs. 
Kruskal–Wallis test with Dunn’s test for multiple 
comparisons: **P < 0.01, ***P < 0.001.
Figure 5
Location of a-SMA-positive vessels in all MTCs (A) and in tumor subgroups 
defined by RET status (B). T, tumor; T/N peritumoral non-neoplastic tissues 
(vessels located within 2 mm of the tumor front are considered 
peritumoral); N, non-neoplastic tissues at a distance (>2 mm) from the 
tumor. Bars indicate mean numbers of a-SMA positive vessels; whiskers 
indicate standard error. ***P < 0.001. Differences were assessed with 
one-way RM ANOVA (panel A) or two-way RM ANOVA with Bonferroni’s 
post-test (panel B).
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(Supplementary Fig. 3A). Podoplanin-positive lymphatic 
endothelial cells were virtually absent within the tumor 
but very abundant in zone T/N (Supplementary Fig. 3B). 
RETmut and RETwt tumors were not significantly different 
in terms of intratumoral CD31-positive vessel counts or 
peritumoral counts of podoplanin-positive lymphatic 
vessel (Supplementary Fig.  3C and D). Remodeling of 
the microvasculature was identified by a-SMA labeling 
of pericytes. All MTCs contained numerous intra- and 
peritumoral microvessels that were a-SMA positive. Mean 
a-SMA-positive vessel counts in zone T were significantly 
higher than those observed in zone T/N, and the difference 
was even more significant relative to findings in zone N 
(Fig. 5A). Mean intratumoral a-SMA-positive vessel counts 
in RETmut tumors were significantly higher than those 
of the RETwt subgroup (Fig. 5B). Again, this was mainly 
the result of differences between the RETmut and RASmut 
subgroups (Supplementary Fig.  4). Figure  6 shows an 
example of CD31, podoplanin and a-SMA staining in 
a RETmut MTC. There were no significant differences 
between the three MTC genotype groups in terms of 
a-SMA-positive vascular cell counts in zones T/N and N 
(Fig. 5B and Supplementary Fig. 4). Considered separately, 
however, RASmut T/N counts were lower than those for 
RETwt/RASwt tumors (Supplementary Fig. 4).
Discussion
A rich vascular supply is essential for tumor growth and 
metastasis. This need is met in part by the generation of 
new blood vessels from existing vascular networks (Turner 
et al. 2003, Roca & Adams 2007, Sakurai & Kudo 2011). 
Angiogenesis is a very complex process mediated by 
the coordinated activities of stimulatory and inhibitory 
factors. Published data on the expression of these 
factors in MTC are scarce, and most regard a limited set 
of proangiogenic proteins (generally, VEGF, PDGFRb 
and VEGFR1, 2 and 3) (Rodriguez-Antona et  al. 2013, 
Mancikova et  al. 2014). No attempt has been made to 
quantitatively assess angiogenesis activation in MTCs as 
a function of the tumor’s mutation profile.
Our findings indicate that the angiogenesis that 
occurs in MTCs harboring RET mutations may be more 
intense and complete than that occurring in MTCs with 
wild-type RET. This conclusion is supported by our 
analysis of transcript levels in MTCs of genes encoding 
key components of important pathways involved in 
the enhancement of tumoral blood supplies. The genes 
that were upregulated play roles in all the main steps 
of angiogenesis: I. the induction of endothelial cell 
proliferation and migration and the enhancement of their 
survival (VEGF pathway); II. detachment of pericytes and 
vascular smooth muscle cells from preexisting vessels 
(angiopoietin 2); III. remodeling of the extracellular 
matrix (metalloproteases and their tissue inhibitors); IV. 
Notch pathway activation (ligands, receptors, regulators 
and effectors), which is indispensable for well-oriented 
vascular growth characterized by vessels without 
functional lumens and the absence of excessive sprouting; 
and finally, V. the maturation and stabilization of the 
new vessels through the recruitment of pericytes (PDGF 
pathway, NOTCH3 and angiopoietin 1) (Mitchell & Parangi 
2005, Carmeliet et al. 2009, Phng & Gerhardt 2009, Raza 
et al. 2010, Sakurai & Kudo 2011, Garcia & Kandel 2012, 
Thomas et al. 2013). Almost all the proangiogenic genes 
we analyzed displayed significantly higher mRNA levels in 
the RETmut tumors than in those with wild-type RET, and 
the involvement of RET activation in this upregulation 
was confirmed by the results observed when the gene was 
silenced with siRNA in MTC cell lines. In vitro experiments 
showed that in MTC cells, oncogenic RET mutations can 
activate VEGFRs and PDGFRs, but they probably do not 
activate Notch signaling, as demonstrated by the stable 
expression levels after RET knockdown of all the Notch 
Figure 6
Immunohistochemical analysis of vascular density 
in an RET-mutated MTC. CD31-positive vessels 
were counted to estimate microvascular density, 
podoplanin-positive vessels were counted to 
estimate lymphatic vascular density and α smooth 
muscle actin (a-SMA)-positive vessels were 
counted to assess vascular pericyte density. In the 
figure immunostained with the anti-podoplanin 
antibody, arrows indicate the interface between 
the tumor (T) and the surrounding non-neoplastic 
peritumoral tissue (N); the figures immunostained 
with CD31 and a-SMA antibodies show only 
intratumoral vessels. Magnification: 200×.  
A full colour version of this figure is available  
at http://dx.doi.org/10.1530/ERC-16-0132.
AUTHOR COPY ONLY
674Research A Verrienti et al. Increased angiogenesis in  
RET-mutated MTCs
En
d
o
cr
in
e-
R
el
at
ed
 C
an
ce
r
DOI: 10.1530/ERC-16-0132
http://erc.endocrinology-journals.org © 2016 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
23:8
pathway effector genes tested (except HES5 in MZ-CRC1 
cells). Interestingly, however, RET activation induced the 
expression of NOTCH ligands, DLL4 and JAG1, raising the 
possibility that MTC cells themselves might contribute 
to angiogenesis by activating Notch signaling in nearby 
endothelial cells.
IHC revealed that all the MTCs were characterized by 
significantly higher expression of all the proangiogenic 
proteins considered and increased MVDs in the tumor 
itself, as compared with corresponding peritumoral and 
normal thyroid tissues. No genotype-related differences 
were detected in the intratumoral expression levels of 
VEGFR2, VEGFR3 or PDGFRa. In contrast, the expression 
of VEGFR1, PDGFB and NOTCH3 was significantly 
upregulated in the RETmut cancers (vs those in the RETwt 
group), confirming the picture that emerged from our 
transcriptional analysis. (Again, these differences were 
especially marked when RETmut MTCs were compared 
with the subset of RETwt tumors that harbored mutations 
involving RAS). PDGFB and NOTCH3 are mainly involved 
in the recruitment of pericytes, and their overexpression 
in RETmut MTCs is in line with our IHC data on the 
expression of a-SMA, a common pericyte marker (Stapor 
et al. 2014). Although MVDs in RETmut and RETwt tumors 
were similar, those in the former group contained higher 
numbers of intratumoral microvessels that were covered 
by pericytes. The essential roles played by pericytes in 
vessel sprouting and the maturation and stabilization of 
new vessels are well established (Baluk et al. 2003, Bergers 
& Song 2005, Ribatti et  al. 2011, Ribeiro & Okamoto 
2015). Collectively, therefore, our findings suggest that 
RETmut MTCs may be characterized by more intense 
activation of angiogenesis and that this oncogene exerts 
particularly powerful effects on the remodeling of the 
tumoral microvasculature, which may be associated 
with variations in its function (Eberhard et  al. 2000, 
Morikawa et al. 2002, Baluk et al. 2003, Azzi et al. 2013). 
The differences in angiogenesis state observed between 
RETmut and RASmut tumors are difficult to explain since 
RAS itself is activated by RET. It is important to consider, 
however, that RET can also be activted by pathways other 
than the MAPK and PI3K cascades, as recently reported by 
Bagheri-Yarmand and coworkers (Bagheri-Yarmand et al. 
2015).
These findings have potentially important implications 
in this era of personalized medicine, in which the genetic 
signatures of tumors are used to inform treatment choices 
(Longo 2012). Our data suggest that the RET mutation 
status of an MTC could conceivably influence the 
tumor’s response to antiangiogenic drugs, such as TKIs. 
If, as we hypothesize, activation of angiogenesis in RET-
mutated tumors is particularly intense and complete, it 
is reasonable to speculate that these tumors might also 
be particularly responsive to TKI-mediated repression 
of this process, as compared with RET wild-type MTCs, 
including those with RAS mutations. Only one study has 
compared in vivo TKI efficacies in patients with RETmut 
and RASmut tumors. The drug in this case, cabozantinib, 
produced similar response rates in both groups of tumors, 
although progression-free survival was appreciably (but 
not significantly) longer in the RETmut group (60 weeks 
vs 47 weeks in the RASmut group) (Sherman et al. 2013). 
It is important to note, however, that the response to 
cabozantinib might also be influenced by the presence of 
pericytes, which are not targeted by this drug and appear 
to be more abundant on the blood vessels of RETmut 
tumors. The assumption that ablation of these cells 
renders tumor vessels more accessible to anti-VEGF drugs 
and consequently more sensitive to their effects (Ribatti 
et  al. 2011) is supported by data generated in several 
experimental models, which show that combined anti-
PDGF/anti-VEGF therapy produces greater tumor vessel 
regression than anti-VEGF therapy alone (Bergers et  al. 
2003, Erber et al. 2003, Bergers & Song 2005, Raza et al. 
2010). If this assumption is correct, one might reasonably 
expect this combination therapy to produce particularly 
obvious benefits in RETmut MTCs than in those without 
these mutations. Indirect support for this hypothesis has 
emerged from a recent study on metastatic clear-cell renal 
cell carcinomas, which showed that the subset of tumors 
whose vasculatures displayed high pericyte coverage 
tumors responded better than tumors without this feature 
to treatment with sunitinib, a multikinase inhibitor with 
strong effects on both PDGFRb and VEGFRs (Kim et  al. 
2014). Additional preclinical evidence is needed, however, 
before this hypothesis can be adequately evaluated.
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